Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Carboplatin

Known as: CBDCA, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II), (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum 
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two… Expand
National Institutes of Health

Related topics

Related topics

44 relations

Broader (2)

Antineoplastic AgentsCisplatin

Narrower (12)

BIC protocolCIV protocolCarbo-MVE protocolDWA 2114
Expand
CAC protocolCTCb regimenCarboplatin 10 MG/ML Injectable SolutionCarboplatin/Neovastat/Paclitaxel
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The side effects of platinum-based chemotherapy drugs: a review for chemists.
The platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2017
Review
2017
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung Cancer: A Systematic Review
Importance The 2 most common chemotherapy regimens used concurrently with thoracic radiation for patients with unresectable IIIA… Expand
  • table 1
  • table 1
  • table 2
  • table 2
  • table 4
Highly Cited
2010
Highly Cited
2010
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
 
Highly Cited
2009
Highly Cited
2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
BACKGROUND Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2006
Highly Cited
2006
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2004
Highly Cited
2004
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer…
PURPOSE To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or… Expand
Highly Cited
2004
Highly Cited
2004
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
PURPOSE Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal… Expand
Highly Cited
2003
Highly Cited
2003
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
PURPOSE In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in… Expand
Highly Cited
1989
Highly Cited
1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
A dosage formula has been derived from a retrospective analysis of carboplatin pharmacokinetics in 18 patients with pretreatment… Expand
Highly Cited
1988
Highly Cited
1988
CARBOPLATIN OR CISPLATIN?
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE